Tirzepatide significantly reduces weight and diabetes risk in patients with obesity and prediabetes

As­traZeneca’s block­buster asth­ma and COPD drug Sym­bi­cort, which brought in $2.5 bil­lion for the phar­ma gi­ant in 2022, now has a gener­ics com­peti­tor from Vi­a­tris.

Apel­lis Phar­ma­ceu­ti­cals is in cash-sav­ing mode as it looks to ward off a new­ly-mint­ed com­peti­tor in treat­ing a lead­ing cause of blind­ness. The drug­mak­er said